CM Life Sciences II Inc. (CMIIU): Price and Financial Metrics

CM Life Sciences II Inc. (CMIIU): $11.22

0.64 (-5.40%)

POWR Rating

Component Grades








CMIIU Price/Volume Stats

Current price $11.22 52-week high $15.89
Prev. close $11.86 52-week low $10.02
Day low $11.06 Volume 33,700
Day high $11.85 Avg. volume 193,992
50-day MA $12.10 Dividend yield N/A
200-day MA $0.00 Market Cap N/A

CMIIU Stock Price Chart Interactive Chart >

CM Life Sciences II Inc. (CMIIU) Company Bio

CM Life Sciences II Inc. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

CMIIU Latest News Stream

Event/Time News Detail
Loading, please wait...

CMIIU Latest Social Stream

Loading social stream, please wait...

View Full CMIIU Social Stream

Latest CMIIU News From Around the Web

Below are the latest news stories about CM Life Sciences II Inc that investors may wish to consider to help them evaluate CMIIU as an investment opportunity.

Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina. “We are honored to have this caliber of experience and leadership join our new board at Biosplice,” said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice. “Ms. Gray, Ms. McGinnis, and Mr. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the f...

Yahoo | April 20, 2021

CM Life Sciences II Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about April 15, 2021

CM Life Sciences II Inc. (Nasdaq: CMIIU) (the "Company") today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about April 15, 2021.

Yahoo | April 13, 2021

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Union Acquisition Corp. II (NASDAQ:LATN), Qell Acquisition Corp. (NASDAQ:QELL), CM Life Sciences II Inc. (NASDAQ:CMIIU)

BALA CYNWYD, PA / ACCESSWIRE / April 2, 2021 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.

Yahoo | April 2, 2021

CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten Investors

Graphic Source: CM Life Sciences, Inc./SomaLogic Introduction: What is CM Life Sciences II? CM Life Sciences II, Inc. (NASDAQ: CMIIU) is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021. CM Life Sciences II was founded to take advantage of the fragmentation of the...

Gunner Laine Hardy on Seeking Alpha | April 1, 2021

CM Life Sciences II stock rallies for fourth day following SPAC deal for SomaLogic

Special purpose acquisition company CM Life Sciences II Inc. (CMIIU) rallied for the fourth straight session Thursday, gaining as much as 15.4% intraday as Wall Street continued to endorse its plan to buy SomaLogic at a $1.2B valuation.CMIIU rose to as high as $14.77 during the session, although it later...

Seeking Alpha | April 1, 2021

Read More 'CMIIU' Stories Here

CMIIU Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -19.86%
5-year N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!